Daily Respiratory Research Analysis
Analyzed 152 papers and selected 3 impactful papers.
Summary
Three standout studies advance respiratory science and care: a Nature Biomedical Engineering study introduces a microphysiological asthma model revealing how mechanical airway constriction drives fibrosis and vascular remodeling; a Nature Communications paper identifies host N-myristoyltransferase 1 inhibition as a broad antiviral strategy against SARS-CoV-2 (and RSV), disrupting virion egress and infectivity; and a meta-analysis of RCTs shows high-flow nasal cannula performs similarly to noninvasive ventilation after extubation in high-risk patients.
Research Themes
- Mechanobiology and microphysiological modeling in asthma
- Host-directed antiviral therapies targeting viral egress
- Post-extubation respiratory support strategies (HFNC vs NIV)
Selected Articles
1. Mechanical force-induced tissue remodelling in a clinically relevant microphysiological model of asthmatic human lungs.
This study introduces a pneumatically actuated lung microphysiological platform that recapitulates distal airway constriction. It demonstrates that compressive mechanical loading drives subepithelial fibrosis and increased airway vascularity in asthma, identifies proteomic mediators, and shows feasibility of pharmacologic modulation.
Impact: It provides a mechanistic, human-relevant link between airway mechanics and tissue remodeling, offering a powerful translational testbed for antifibrotic and vascular-modulating therapies in asthma.
Clinical Implications: While preclinical, the platform enables mechanism-informed screening of anti-fibrotic and anti-angiogenic interventions and suggests that targeting subepithelial fibrosis may normalize airway vascularity in asthma.
Key Findings
- A soft-actuated airway-on-chip model reproduced distal airway constriction and compressive force-induced fibrotic remodeling.
- Subepithelial fibrosis emerged as a key driver of increased airway vascularity in asthma.
- Proteomic analysis identified mediators of abnormal remodeling, and pharmacologic modulation was feasible in the system.
Methodological Strengths
- Integration of pneumatically addressable soft actuators enabling physiologic mechanical loading.
- In vivo validation and incorporation of vascularized airway constructs with proteomic profiling.
Limitations
- Preclinical in vitro model may not fully capture complex in vivo immune and multicellular interactions.
- Therapeutic findings are proof-of-concept without clinical outcome data.
Future Directions: Leverage the platform for head-to-head testing of anti-fibrotic and anti-angiogenic agents, incorporate immune components, and correlate chip-derived biomarkers with patient samples to inform precision trials.
Structural remodelling of living tissues due to mechanical forces is a common occurrence that plays an essential role in development, health and disease, but preclinical investigation of this dynamic process in human-relevant conditions remains a challenge. Here we present a microphysiological system integrated with pneumatically addressable soft actuators to emulate dynamic mechanical loading of mucosal tissues in the human respiratory tract. Using this system, we created a clinically relevant model of airway constriction in distal regions of asthmatic lungs to show compressive force-induced fibrotic airway remodelling. Following in vivo validation, we generated vascularized airway constructs in this model to investigate abnormal vascular remodelling in asthma, revealing airway constriction-induced subepithelial fibrosis as a key contributor to increased vascularity of asthmatic airways. Furthermore, we identified molecular mediators of abnormal airway remodelling through proteomics analysis of our microphysiological system and tested the feasibility of pharmacologically modulating their activity. We believe that our technology provides a useful tool for studying biophysical control and dysregulation of dynamic tissue remodelling in lungs and other mechanically active organs.
2. Inhibition of host N-myristoylation compromises the infectivity of SARS-CoV-2 due to Golgi-bypassing egress.
Pharmacologic or genetic inhibition of host NMT1 broadly reduces SARS-CoV-2 (and RSV/VSV) infection across primary airway cells and brain organoids. Mechanistically, NMT1 blockade forces ER/lysosome-mediated, Golgi-bypassing egress that disrupts spike maturation, yielding less infectious progeny.
Impact: Reveals a host-directed antiviral mechanism less prone to viral escape and uncovers a fundamental egress pathway alteration that compromises infectivity.
Clinical Implications: NMT1 emerges as a promising host target for broad antiviral development against respiratory viruses, warranting medicinal chemistry and in vivo studies to evaluate efficacy and safety.
Key Findings
- NMT1 inhibition or knockdown significantly impairs SARS-CoV-2, RSV, and VSV infections across diverse human cell systems.
- Blocking N-myristoylation induces ER/lysosome-mediated, Golgi-bypassing egress, disrupting spike maturation and virion composition.
- Host-directed antiviral activity was demonstrated in primary nasal epithelial cells and brain organoids, supporting translational relevance.
Methodological Strengths
- Use of multiple human-relevant systems including primary nasal epithelial cells and brain organoids.
- Mechanistic dissection of viral egress with convergent phenotypes across viruses.
Limitations
- Preclinical without in vivo pharmacokinetic/toxicity data.
- Specificity and druggability of NMT1 inhibitors require further evaluation.
Future Directions: Advance selective NMT1 inhibitors into animal models of respiratory viral infection; map N-myristoylated host/viral substrates mediating the egress phenotype; evaluate resistance barriers.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which caused the coronavirus disease 2019 (COVID-19) pandemic, remains a global health concern despite vaccines, neutralizing antibodies, and antiviral drugs. The emergence of viral mutations that diminish the effectiveness of current interventions underscores the importance of alternative, host-directed strategies. Here, we show that pharmacological inhibition or knockdown of host N-myristoyltransferase 1 (NMT1), one of the two human enzymes that mediates protein N-myristoylation, significantly impairs SARS-CoV-2, Vesicular Stomatitis Virus (VSV) and Respiratory syncytial virus (RSV) infections. We demonstrate the antiviral efficacy and safety of this host-directed therapeutic strategy across multiple viral tropic sites, including human lung adenocarcinoma cell lines, primary nasal epithelial cells, and human choroid plexus-cortical brain organoids. NMT1 inhibition triggers a Golgi-bypassing pathway for SARS-CoV-2 progeny virion egress, through endoplasmic reticulum and lysosomal structures, which leads to perturbed progeny virion composition and spike maturation, impairing progeny virion infectivity.
3. High-flow Nasal Therapy vs Noninvasive Ventilation for Post-extubation Patients at High Risk of Reintubation: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Across 11 RCTs (n=2765), HFNC did not increase reintubation within 72 hours or 7 days versus NIV, and mortality rates were similar. Findings support HFNC as a reasonable alternative when NIV is not tolerated or feasible in high-risk post-extubation patients.
Impact: Synthesizes RCT evidence directly informing post-extubation respiratory support, potentially broadening safe use of HFNC in high-risk populations.
Clinical Implications: Clinicians may consider HFNC as an alternative to NIV after extubation in high-risk patients, particularly when comfort, tolerance, or resource constraints limit NIV, while recognizing heterogeneity across trials.
Key Findings
- No significant difference between HFNC and NIV for reintubation within 72 hours (RR 1.22, 95%CI 0.83–1.80) or 7 days (RR 1.23, 95%CI 0.90–1.69).
- Mortality outcomes (ICU, in-hospital, 28-day) and post-extubation respiratory failure were similar between modalities.
- GRADE assessment ranged from very low to moderate, highlighting variability in certainty and definitions.
Methodological Strengths
- Restriction to randomized controlled trials with predefined primary endpoint (72-hour reintubation).
- Use of GRADE framework to rate certainty of evidence.
Limitations
- Heterogeneity in trial definitions and patient selection may limit generalizability.
- Some outcomes had low or very low certainty per GRADE.
Future Directions: Standardize outcome definitions and high-risk criteria; evaluate patient-centered outcomes (comfort, tolerance) and cost-effectiveness of HFNC vs NIV in pragmatic trials.
BACKGROUND: Current guidelines recommend noninvasive ventilation (NIV) over high-flow nasal cannula (HFNC) in patients at high risk of extubation failure. This systematic review and meta-analysis aimed to compare the efficacy of HFNC vs NIV in post-extubation patients at high risk of reintubation. METHODS: A systematic search was conducted in PubMed, Embase, Cochrane Library, and ClinicalTrials.gov without language restrictions. Randomized controlled trials (RCTs) evaluating HFNC vs NIV in post-extubation patients were included. The primary outcome was reintubation within 72h. Effect estimates were pooled as risk ratios (RR) with 95%CI. Certainty of evidence was assessed using the GRADE (Grading of Recommendations Assessment, Development, and Evaluation) framework and categorized as high, moderate, low, or very low. RESULTS: Eleven RCTs (n=2765 patients) met inclusion criteria. No statistically significant differences were observed between HFNC and NIV for reintubation within 72h (RR, 1.22; 95%CI, 0.83-1.80; moderate), reintubation within 7 days (RR, 1.23; 95%CI, 0.90-1.69; low), post-extubation respiratory failure (RR, 0.82; 95%CI, 0.66-1.02; moderate), intensive care unit (ICU) mortality (RR, 0.90; 95%CI, 0.63-1.29; very low), in-hospital mortality (RR, 0.96; 95%CI, 0.74-1.25; moderate), or 28-day mortality (RR, 0.99; 95%CI, 0.59-1.65; moderate). CONCLUSIONS: Compared with NIV, HFNC was not associated with increased reintubation or mortality. However, variability in study definitions may limit direct applicability to bedside decision-making in individual high-risk patients.